Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
This trial is active, not recruiting.
|Sponsor||Teva Branded Pharmaceutical Products, R&D Inc.|
|Start date||July 2012|
|End date||July 2017|
|Trial size||100 participants|
|Trial identifier||NCT01596621, C18083/3076|
The primary objective of the study is to determine the overall response rate (ORR), which includes complete response (CR) and partial response (PR), to bendamustine treatment in patients with indolent non-Hodgkin lymphoma (NHL) that has progressed after rituximab or a rituximab-containing therapy.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Beijing, China||Teva Investigational Site 001||no longer recruiting|
|Beijing, China||Teva Investigational Site 002||no longer recruiting|
|Beijing, China||Teva Investigational Site 003||no longer recruiting|
|Beijing, China||Teva Investigational Site 004||no longer recruiting|
|Beijing, China||Teva Investigational Site 016||no longer recruiting|
|Beijing, China||Teva Investigational Site 021||no longer recruiting|
|Beijing, China||Teva Investigational Site 022||no longer recruiting|
|Changchun, China||Teva Investigational Site 015||no longer recruiting|
|Chengdu, China||Teva Investigational Site 010||no longer recruiting|
|Guangzhou, Guangdong Province, China||Teva Investigational Site 008||no longer recruiting|
|Guangzhou, China||Teva Investigational Site 007||no longer recruiting|
|Hangzhou, , Zhejiang, China||Teva Investigational Site 011||no longer recruiting|
|Harbin, China||Teva Investigational Site 019||no longer recruiting|
|Lanzhou, China||Teva Investigational Site 024||no longer recruiting|
|Nanjing, Jiangsu Province, China||Teva Investigational Site 013||no longer recruiting|
|Nanjing,Jiangsu Province, China||Teva Investigational Site 012||no longer recruiting|
|Shanghai, China||Teva Investigational Site 005||no longer recruiting|
|Shanghai, China||Teva Investigational Site 006||no longer recruiting|
|Sushow, China||Teva Investigational Site 020||no longer recruiting|
|Zhengzhou, China||Teva Investigational Site 017||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Overall response rate (ORR)
time frame: up to 24 weeks
Duration of response (DOR) for patients who achieved a best response of PR or better
time frame: up to 2.5 Years
Progression-free Survival for all patients
time frame: up to 2.5 Years
time frame: Prior to the start of infusion on Day 1 for up to 24 hours during Cycle 1
time frame: From signing of the informed consent form through 30 days after the last administration
Male or female participants at least 18 years old.
- The patient has documented relapse from indolent B-cell NHL. Patients with the following subtypes of indolent NHL are eligible for this study:
- small lymphocytic lymphoma (peripheral B cell count <5000 cells/mm3)
- lymphoplasmacytic lymphoma
- splenic marginal zone B-cell lymphoma (±villous lymphocytes)
- extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type
- nodal marginal zone lymphoma (±monocytoid B-cells)
- follicle center lymphoma
- follicular (grade 1, 2, or 3a) lymphoma
- The patient has disease documented to have progressed despite rituximab treatment. The patient's disease is considered to be rituximab refractory if any of the following criteria are met at any time during the patient's treatment history (progression must be documented by computed tomography [CT] scan or magnetic resonance imaging [MRI] or biopsy) or if a patient has palpable lymph nodes that were well documented in size and, after rituximab treatment, palpable disease remains or comes back [CT, MRI, or biopsy is preferred and performed whenever possible to document progressive disease(PD)]:
- rituximab-only regimen: Patients who receive a full course of single-agent rituximab (at least 2 doses of 375 mg/m2 [or a therapeutically-active dose] weekly) and have no response (do not obtain a PR or better) to treatment or progress after a full regimen of rituximab was given.
- rituximab maintenance therapy or extended schedule: Patients who have a history of a full course of rituximab (at least 2 doses of 375 mg/m2 [or a therapeutically-active dose] as a single agent [weekly] or in combination with chemotherapy [day 1 of each of 4 cycles]) and are on a maintenance regimen, and progress before the next scheduled rituximab dose or after completing a maintenance rituximab regimen.
- rituximab-chemotherapy combination regimen: Patients who receive a full course of rituximab (at least 2 doses of 375 mg/m2 or a therapeutically-active dose [on day 1 of each of 2 cycles]) in combination with chemotherapy and have no response (do not obtain a PR or better) to treatment or progress after the last dose of rituximab in a regimen.
- full rituximab exposure treatment: Patients who have a history of a full course of rituximab treatment (at least 2 doses of 375 mg/m2 [or a therapeutically-active dose] as a single agent or in combination with chemotherapy) and, in a subsequent rituximab/chemotherapy combination regimen, have no response (do not obtain a PR or better) to treatment or progress after the last dose of rituximab in a given regimen, even if the subsequent regimen included less than 2 doses of rituximab. Patients could receive additional systemic treatment after the qualifying rituximab regimen.
- The patient has received treatment with at least 1, but no more than 3, previous chemotherapy regimens. A regimen is defined as a new treatment combination or agent. Retreatment with the identical regimen or agent does not count as a new regimen; however, change from cyclophosphamide, vincristine, and prednisolone (CVP) to cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is counted as a new regimen. Rituximab, radioimmunotherapy, or other biologic treatments not combined with chemotherapy are not counted as a regimen.
- The patient has a bidimensionally measurable disease with at least 1 lesion measuring 2.0 cm or more in a single dimension. Patients who have previous involved-field irradiation can be included, provided the irradiated area is not the only source of measurable disease.
- The patient is at least 18 years old at the time of informed consent.
- The patient has a WHO performance status of 0, 1, or 2.
- The patient has absolute neutrophil count (ANC) 1000 cells/mm3 or more and platelet count 85000 cells/mm3 or more.
- The patient has a creatinine clearance of more than 30 mL/min as determined by the Cockcroft-Gault calculation.
- The patient has adequate hepatic function (no more than 2.5 times the ULN for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and no more than 1.5 times the upper limit of the normal range (ULN) for total bilirubin). Patients with nonclinically significant elevations of bilirubin due to Gilbert's disease are eligible.
- The patient has had a bone marrow biopsy within 6 weeks before the 1st dose of bendamustine.
- Women of childbearing potential (not surgically sterile or 1 year postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method starting 2 weeks before the start of study drug treatment, during study drug treatment, and for 3 months after the end of study drug treatment. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- Women of childbearing potential must have a negative serum or urine pregnancy test.
- Men not surgically sterile or who are capable of producing offspring must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method starting 2 weeks before the start of study drug treatment, during study drug treatment, and for 3 months after the end of study drug treatment.
- The patient has an estimated life expectancy of at least 3 months.
- The patient (or patient's legal representative) provides written informed consent.
- The patient has received previous radiotherapy, radioimmunotherapy, chemotherapy, or immunotherapy within 4 weeks before day 1 of cycle 1 or has failed to recover (to Common Terminology Criteria for Adverse Events [CTCAE] toxicity grade 1 or 2) from clinically significant nonhematologic adverse events due to any agents administered previously.
- The patient has received treatment with an investigational agent within 4 weeks of day 1 of cycle 1.
- The patient has received hematopoietic growth factors within 4 weeks of day 1 of cycle 1. However, patients receiving chronic erythropoietin treatment are eligible for inclusion in this study.
- The patient has a history of previous high-dose chemotherapy with allogeneic stem cell support (history of autologous stem cell support is permissible).
- The patient is receiving or has received treatment with therapeutic doses of systemic steroids within 4 weeks of day 1 of cycle 1. (Low doses of chronic steroids [prednisone or equivalent] up to 20 mg/day for non-neoplastic disorders or for indications other than lymphoma or lymphoma-related complications are permitted.)
- The patient has transformed disease.
- The patient has any history of central nervous system (CNS) or leptomeningeal lymphoma.
- The patient has, or has had within the past 5 years, an active malignancy other than the target cancer. The exceptions are prostate cancer (Gleason grade <6 with prostate specific antigen (PSA) levels within the normal range), in situ cervical or breast carcinoma, and nonmelanoma skin cancer that have received definitive treatment.
- The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study immediately.)
- The patient has a serious infection, medical condition, or psychiatric condition that, in the opinion of the investigator, might interfere with the achievement of the study objectives.
- The patient is known to be positive for human immunodeficiency virus (HIV), have active hepatitis B, or active hepatitis C (anti-hepatitis C virus [HCV] positive). Hepatitis B surface antigen must be tested. The determination of active disease is left up to the Investigator.
- The patient has a known hypersensitivity to mannitol.
- The patient has used bendamustine previously.
|Official title||An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment|
|Description||This is a multicenter, nonrandomized, open-label, single-agent clinical study conducted in China, and is designed to investigate the use of bendamustine in the treatment of Chinese patients with relapsed, rituximab-refractory indolent NHL. The study consists of a screening period of up to 4 weeks, a treatment period of approximately 24 weeks (up to eight 21-day cycles), and a long-term follow-up period for up to 2 years after the last dose of study drug. Patients are expected to participate in this study for approximately 2.5 years.|
Call for more information